BINEX Co. Ltd - Asset Resilience Ratio
BINEX Co. Ltd (053030) has an Asset Resilience Ratio of 0.43% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore 053030 total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how BINEX Co. Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of BINEX Co. Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BINEX Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BINEX Co. Ltd (053030) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.30 Billion | 0.43% |
| Total Liquid Assets | ₩1.30 Billion | 0.43% |
Asset Resilience Insights
- Limited Liquidity: BINEX Co. Ltd maintains only 0.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BINEX Co. Ltd Industry Peers by Asset Resilience Ratio
Compare BINEX Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 40.42% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
Annual Asset Resilience Ratio for BINEX Co. Ltd (2004–2024)
The table below shows the annual Asset Resilience Ratio data for BINEX Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.63% | ₩1.77 Billion ≈ $1.20 Million |
₩279.39 Billion ≈ $189.34 Million |
-1.43pp |
| 2023-12-31 | 2.06% | ₩5.29 Billion ≈ $3.59 Million |
₩257.01 Billion ≈ $174.17 Million |
-10.74pp |
| 2022-12-31 | 12.80% | ₩38.20 Billion ≈ $25.89 Million |
₩298.41 Billion ≈ $202.23 Million |
-6.82pp |
| 2021-12-31 | 19.62% | ₩53.47 Billion ≈ $36.24 Million |
₩272.49 Billion ≈ $184.66 Million |
-5.08pp |
| 2020-12-31 | 24.71% | ₩66.73 Billion ≈ $45.22 Million |
₩270.09 Billion ≈ $183.04 Million |
+12.62pp |
| 2019-12-31 | 12.09% | ₩24.51 Billion ≈ $16.61 Million |
₩202.78 Billion ≈ $137.42 Million |
+1.23pp |
| 2018-12-31 | 10.86% | ₩20.67 Billion ≈ $14.01 Million |
₩190.42 Billion ≈ $129.05 Million |
-0.94pp |
| 2017-12-31 | 11.79% | ₩19.79 Billion ≈ $13.41 Million |
₩167.77 Billion ≈ $113.70 Million |
+7.86pp |
| 2016-12-31 | 3.94% | ₩6.97 Billion ≈ $4.72 Million |
₩177.10 Billion ≈ $120.02 Million |
+2.92pp |
| 2015-12-31 | 1.01% | ₩1.78 Billion ≈ $1.21 Million |
₩176.11 Billion ≈ $119.35 Million |
-0.97pp |
| 2013-12-31 | 1.98% | ₩2.42 Billion ≈ $1.64 Million |
₩122.27 Billion ≈ $82.86 Million |
-1.17pp |
| 2012-12-31 | 3.15% | ₩4.53 Billion ≈ $3.07 Million |
₩143.80 Billion ≈ $97.45 Million |
+0.82pp |
| 2011-12-31 | 2.33% | ₩2.35 Billion ≈ $1.59 Million |
₩100.68 Billion ≈ $68.23 Million |
+1.72pp |
| 2007-12-31 | 0.61% | ₩301.36 Million ≈ $204.23K |
₩49.13 Billion ≈ $33.29 Million |
-4.39pp |
| 2006-12-31 | 5.00% | ₩2.32 Billion ≈ $1.57 Million |
₩46.30 Billion ≈ $31.38 Million |
+1.84pp |
| 2005-12-31 | 3.17% | ₩1.35 Billion ≈ $912.81K |
₩42.55 Billion ≈ $28.83 Million |
-4.33pp |
| 2004-12-31 | 7.49% | ₩2.38 Billion ≈ $1.61 Million |
₩31.76 Billion ≈ $21.52 Million |
-- |
About BINEX Co. Ltd
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more